Bioprojet is investing in a new research center dedicated to the research for the treatment of neurological disorders

With this future 7,000 m² laboratory in Saint-Grégoire, our ambition is to double our research capacity and accelerate therapeutic innovation in areas with major public health challenges.

A structuring project, designed to host over 100 researchers by 2027 and strengthen our unique drug discovery model, based on the creation of new molecules and bold fundamental research.

An investment of 25 million euros supported by an independent and self-financed model : at Bioprojet, 40% of the annual revenue is reinvested in R&D.

For us, agility, scientific rigor, and human commitment are the keys to sustainable innovation. This is our vision of Smart Pharma.